---
title: "FDA approves AbbVie’s JUVMO for adults with Parkinson’s disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300301299.md"
description: "The FDA has approved AbbVie’s JUVMO (tavapadon) tablets for treating Parkinson’s disease in adults. This marks the first selective D1/D5 receptor agonist available in the US. The label permits once-daily dosing as monotherapy or combined with levodopa to manage motor symptoms throughout the disease course. AbbVie anticipates patient availability in the US by October 2026."
datetime: "2026-09-28T12:02:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300301299.md)
  - [en](https://longbridge.com/en/news/300301299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300301299.md)
generator: "portal-rs"
---

# FDA approves AbbVie’s JUVMO for adults with Parkinson’s disease

-   FDA cleared AbbVie’s JUVMO (tavapadon) tablets for adults with Parkinson’s disease, marking the first selective D1/D5 receptor agonist in the US. \* Label allows once-daily dosing as monotherapy or alongside levodopa to manage motor symptoms across the disease course. \* AbbVie expects US patient availability in October 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280800PR\_NEWS\_USPR\_\_\_\_\_CG55171) on September 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [AbbVie says FDA grants breakthrough therapy status for ABBV-400 in metastatic colorectal cancer](https://longbridge.com/en/news/301144773.md)
- [AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo | ABBV Stock News](https://longbridge.com/en/news/300695604.md)
- [AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates](https://longbridge.com/en/news/300591646.md)
- [AbbVie wins EU approval for paediatric pJIA use](https://longbridge.com/en/news/300559910.md)
- [Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug](https://longbridge.com/en/news/301009449.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**